Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Werewolf Therapeutics, Inc.HOWL · Entity 7244 | Chief Technology Officer | January 02, 2025 | January 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Werewolf Therapeutics, Inc.
Report date January 02, 2025 · Filed January 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.56 · Expires 2034-12-31 | Direct | 150,000 |
Reported balance
After 2025-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-02 · Grant · Acquired 150,000 · Balance 150,000 F1: The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in equal monthly installments over four years, with the initial vesting to commence on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.56 · Expires 2034-12-31 | Direct | 153,129 |
Reported balance
After 2025-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-01-02 · Grant · Acquired 153,129 · Balance 153,129 |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in equal monthly installments over four years, with the initial vesting to commence on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2025 Filed Jan 6, 2025 22:43 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 153,129 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0000950170-25-002342 · ownership.xml · derivative · entry 2 Karunatilake Chulani · CIK 0001867326 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,129 Underlying: Common Stock · 153,129 shares Expires 2034-12-31 Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:43 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0000950170-25-002342 · ownership.xml · derivative · entry 1 Karunatilake Chulani · CIK 0001867326 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-12-31 F1 · derivative.exercise_date: The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in equal monthly installments over four years, with the initial vesting to commence on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:30 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0000950170-24-001915 · ownership.xml · derivative · entry 1 Karunatilake Chulani · CIK 0001867326 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-12-31 F1 · derivative.exercise_date: The option was granted on January 2, 2024 with a Vesting Commencement Date of January 1, 2024. The shares underlying the option vest in equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2028. Read SEC document |
| January 03, 2023 Filed Jan 10, 2023 02:35 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 103,600 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0000899243-23-001408 · doc4.xml · derivative · entry 1 Karunatilake Chulani · CIK 0001867326 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,600 Underlying: Common Stock · 103,600 shares Expires 2032-12-31 F1 · derivative.exercise_date: The option was granted on January 3, 2023 with a Vesting Commencement Date of January 1, 2023. The shares underlying the option vest in equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2027. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:40 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 136,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0000899243-22-020985 · doc4.xml · derivative · entry 1 Karunatilake Chulani · CIK 0001867326 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,000 Underlying: Common Stock · 136,000 shares Expires 2032-05-31 F1 · derivative.exercise_date: The option was granted on June 1, 2022 with a Vesting Commencement Date of June 1, 2022. The shares underlying the option vest over three years, with the shares vesting in equal monthly installments through June 1, 2025. Read SEC document |
| January 06, 2022 Filed Jan 18, 2022 23:29 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 34,258 | $0.00 Strike: $11.55 | $0.00 |
DisclosureSEC source: 0000899243-22-002195 · doc4.xml · derivative · entry 1 Karunatilake Chulani · CIK 0001867326 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,258 Underlying: Common Stock · 34,258 shares Expires 2032-01-05 F1 · derivative.exercise_date: The option was granted on January 6, 2022 with a Vesting Commencement Date of January 1, 2022. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the Vesting Commencement Date and 2.0833% of the shares vesting each month thereafter through January 1, 2026. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 12:26 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 272,000 | $0.00 Strike: $19.23 | $0.00 |
DisclosureSEC source: 0001785530-21-000030 · wf-form4_162522876528536.xml · derivative · entry 1 Karunatilake Chulani · CIK 0001867326 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,000 Underlying: Common Stock · 272,000 shares Expires 2031-06-30 F1 · derivative.exercise_date: The option was granted on July 1, 2021. The shares underlying the option vest over four years, with one-fourth of the shares vesting on the first anniversary of the date of grant and the remaining shares vesting in equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.